< Back to search
Filter
1
Featured

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

for
Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma,
Location: San Antonio TX
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06084481

Phase1, Recruiting
Active & Responsive

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

for
Platinum-resistant Ovarian Cancer,
Location: Stony Brook NY, Greenville NC, Silver Spring MD,
Sponsor: Genelux Corporation

Sex: Female

Age: 18+

Code: NCT05281471

Phase3, Recruiting
Active & Responsive

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

for
Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic,
Location: Hackensack NJ, Fairfax VA, Buffalo NY, Cleveland OH,
Sponsor: Whitehawk Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07444814

Phase1, Recruiting

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

for
Advanced Solid Tumor, Metastatic Solid Tumor,
Location: New York NY, Jacksonville FL, Cleveland OH,
Sponsor: GI Innovation, Inc.

Sex: All

Age: 18+

Code: NCT05824975

Phase1, Phase2, Recruiting

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

for
Platinum-resistant Ovarian Cancer, Recurrent Ovary Cancer,
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18 - 70+

Code: NCT06321484

Phase1, Recruiting

Interested in new platinum-resistant ovarian cancer trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

for
Platinum-resistant Ovarian Cancer, Testicular Cancer,
Location: Boston MA, Providence RI, New York NY, Durham NC,
Sponsor: Context Therapeutics Inc.

Sex: All

Age: 18+

Code: NCT06515613

Phase1, Recruiting

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

for
High Grade Epithelial Ovarian Cancer,
Location: Boston MA, Providence RI, Camden NJ, Doylestown PA,
Sponsor: Genmab

Sex: All

Age: 18+

Code: NCT05579366

Phase1, Phase2, Recruiting

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

for
Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult,
Location: Boston MA, Hackensack NJ, Philadelphia PA, Fairfax VA,
Sponsor: NiKang Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06586957

Phase1, Recruiting

A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer

for
Ovarian Cancer, Platinum-resistant Ovarian Cancer
Location: Abbotsford, Vancouver
Sponsor: British Columbia Cancer Agency

Sex: Female

Age: 18+

Code: NCT04787289

Phase2, Recruiting

GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer

for
Platinum-resistant Ovarian Cancer
Location: Buffalo NY
Sponsor: Roswell Park Cancer Institute

Sex: All

Age: 18+

Code: NCT07489287

Phase1, Recruiting

A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

for
Ovarian Cancer Recurrent, Ovarian Cancer,
Location: Buffalo NY, Detroit MI, Minneapolis MN, Houston TX
Sponsor: Outpace Bio, Inc.

Sex: Female

Age: 18+

Code: NCT07030907

Phase1, Recruiting

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

for
PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
Location: Long Island City NY, Philadelphia PA, Sarasota FL,
Sponsor: Whitehawk Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07470853

Phase1, Recruiting

A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

for
Platinum-resistant Ovarian Cancer
Location: Newport Beach CA, El Segundo CA
Sponsor: ImmunityBio, Inc.

Sex: Female

Age: 18 - 70+

Code: NCT06710288

Phase2, Recruiting

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

for
Ovarian High Grade Serous Adenocarcinoma,
Location: Atlanta GA
Sponsor: Emory University

Sex: Female

Age: 18+

Code: NCT05998135

Phase2, Recruiting

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

for
Platinum-Resistant Ovarian Carcinoma
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: Female

Age: 18+

Code: NCT05225363

Phase1, Recruiting

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

for
Recurrent Ovarian High Grade Serous Adenocarcinoma,
Location: Philadelphia PA, Charlottesville VA, Winston-Salem NC,
Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT04633239

Phase1, Recruiting

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

for
Platinum-Resistant Fallopian Tube Carcinoma,
Location: Scottsdale AZ
Sponsor: Mayo Clinic

Sex: Female

Age: 18+

Code: NCT06483048

Phase1, Recruiting

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

for
Epithelial Ovarian Cancer, Primary Peritoneal,
Location: Boston MA, New Haven CT, New Brunswick NJ, Montreal,
Sponsor: TORL Biotherapeutics, LLC

Sex: Female

Age: 18+

Code: NCT06690775

Phase2, Recruiting

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

for
Ovarian Cancer
Location: Montreal, Winston-Salem NC, Pittsburgh PA, Charlotte NC,
Sponsor: Incyte Corporation

Sex: Female

Age: 18+

Code: NCT07214779

Phase3, Recruiting

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

for
Ovarian Neoplasms
Location: Montreal
Sponsor: GlaxoSmithKline

Sex: Female

Age: 18+

Code: NCT07286266

Phase3, Recruiting